AALL1721 - A Single Arm Phase II Trial to Assess the Efficacy and Safety of CTL019 in First Line High-Risk (HR) Pediatric and Young Adult Patients with B-Cell Acute Lymphoblastic Leukemia (B- ALL) Who are Minimal Residual Disease (MRD) Positive at the End of Consolidation (EOC) Therapy


Total Award Amount

  • 169476.00
  • Direct Costs

  • 124615.00
  • Sponsor Award Id

  • Contributor

  • Ana Galtarossa Xavier   Investigator  
  • Hilary Haines   Investigator  
  • Joseph Chewning III M.D.   Investigator  
  • Julie Wolfson-Stockman M.D.   Investigator  
  • Matthew Kutny M.D.   Principal Investigator